優游50優氟吸入劑

Šalis: Taivanas

kalba: kinų

Šaltinis: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Veiklioji medžiaga:

SALMETEROL XINAFOATE MICRONIZED;;FLUTICASONE PROPIONATE MICRONIZED

Prieinama:

荷商葛蘭素史克藥廠股份有限公司台灣分公司 台北市中正區忠孝西路一段66號23-24樓 (86927438)

ATC kodas:

R03AK06

Vaisto forma:

口腔吸入劑

Sudėtis:

SALMETEROL XINAFOATE MICRONIZED (1216002920) (equivalent to 25mcg of Salmeterol)MCG; FLUTICASONE PROPIONATE MICRONIZED (8406002220) MCG

Vienetai pakuotėje:

金屬罐裝附吸入器

Klasė:

製　劑

Recepto tipas:

須由醫師處方使用

Pagaminta:

GLAXO WELLCOME PRODUCTION 23 RUE LAVOISIER, ZONE INDUSTRIELLE NO.2, 27000 EVREUX, FRANCE FR

Gydymo sritis:

salmeterol and fluticasone

Terapinės indikacijos:

EVOFLO適用於可逆性呼吸道阻塞疾病(ROAD)之常規治療，包括適合使用支氣管擴張劑及皮質類固醇組合療法的兒童與成人。這可能包括正在使用長效乙型作用劑(β-AGONIST)及吸入型皮質類固醇之有效維持劑量的患者。正在接受吸入型皮質類固醇療法，而仍有症狀之患者。接受支氣管擴張劑之常規治療，而需要吸入型皮質類固醇之患者。

Produkto santrauka:

註銷日期: 2018/12/03; 註銷理由: 自請註銷; 有效日期: 2019/02/19; 英文品名: Evoflo 50 Evohaler

Autorizacija statusas:

已註銷

Leidimo data:

2014-02-19

Pakuotės lapelis

EVOFLO™ 50 EVOHALER™
Salmeterol/fluticasone propionate
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single actuation of
_EVOFLO_
provides:
Salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 50
micrograms of fluticasone propionate.
PHARMACEUTICAL FORM
Inhalation aerosol.
CLINICAL PARTICULARS
INDICATIONS
ASTHMA - REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE (ROAD)
_EVOFLO_
is indicated in the regular treatment of reversible obstructive
airways disease (ROAD), including asthma in children and adults,
where use of a combination (bronchodilator and inhaled corticosteroid)
is appropriate.
This may include:
Patients on effective maintenance doses of long-acting
beta-agonists and inhaled corticosteroids.
Patients who are symptomatic on current inhaled
corticosteroid therapy.
Patients on regular bronchodilator therapy who require
inhaled corticosteroids.
DOSAGE AND ADMINISTRATION
_EVOFLO_
Evohaler is for inhalation only.
Patients should be made aware that
_EVOFLO_
Evohaler must be used
regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the
strength
of
_EVOFLO_
they are receiving remains optimal and is only changed on
medical advice.
ASTHMA - REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE (ROAD)
The dose should be titrated to the lowest dose at which effective
control
of symptoms is maintained. Where the control of symptoms is
maintained with twice daily
_EVOFLO_
, titration to the lowest effective
dose could include
_EVOFLO_
given once daily.
Patients should be given the strength of
_EVOFLO_
containing the
appropriate fluticasone propionate dosage for the severity of their
disease.
Recommended Doses:
Adults and adolescents 12 years and older:-
Two inhalations of 25 micrograms salmeterol and 50 micrograms
fluticasone propionate twice daily.
Children 4 years and older:-
Two inhalations of 25 micrograms salmeterol and 50 micrograms
fluticasone propionate twice daily.
There are no data available for use of
_EVOFLO_
in children aged under
4 years.
SPECIAL